Comparison of the clinical performance of PapilloCheck human papillomavirus detection with that of the GP5+/6+-PCR-enzyme immunoassay in population-based cervical screening

Journal of Clinical Microbiology

Volumn 48, Issue 3, 2010, Pages 797-801

  Hesselink, A T ^a   Heideman, D A M ^a   Berkhof, J ^a   Topal, F ^a   Pol, R P ^a   Meijer, C J L M ^a   Snijders, P J F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DNA MICROARRAY; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; WART VIRUS;

ADULT; CLINICAL LABORATORY TECHNIQUES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MASS SCREENING; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY;

HUMAN PAPILLOMAVIRUS;

EID: 77749255724     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.01743-09     Document Type: Article

References (22)

1. Arbyn, M., P. Sasieni, C. J. Meijer, C. Clavel, G. Koliopoulos, and J. Dillner. 2006. Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24(Suppl. 3):S78-S89.
2. Berkhof, J., N. W. Bulkmans, M. C. Bleeker, S. Bulk, P. J. Snijders, F. J. Voorhorst, and C. J. Meijer. 2006. Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol. Biomarkers Prev. 15:1268-1273.
3. Berkhof, J., M. C. de Bruijne, G. D. Zielinski, N. W. Bulkmans, L. Rozendaal, P. J. Snijders, R. H. Verheijen, and C. J. Meijer. 2006. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis. Int. J. Cancer 118:1759-1768.
4. Bulkmans, N., J. Berkhof, L. Rozendaal, F. van Kemenade, A. Boeke, S. Bulk, F. Voorhorst, R. Verheijen, K. van Groningen, M. Boon, W. Ruitinga, M. van Ballegooijen, P. Snijders, and C. Meijer. 2007. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370:1764-1772.
5. Bulkmans, N. W., M. C. Bleeker, J. Berkhof, F. J. Voorhorst, P. J. Snijders, and C. J. Meijer. 2005. Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse. Int. J. Cancer 117:177-181.
6. Bulkmans, N. W., L. Rozendaal, P. J. Snijders, F. J. Voorhorst, A. J. Boeke, G. R. Zandwijken, F. J. van Kemenade, R. H. Verheijen, K. Groningen, M. E. Boon, H. J. Keuning, M. van Ballegooijen, A. J. van den Brule, and C. J. Meijer. 2004. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int. J. Cancer 110:94-101.
7. Dalstein, V., S. Merlin, C. Bali, M. Saunier, R. Dachez, and C. Ronsin. 2009. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus. J. Virol. Methods 156:77-83.
8. Hesselink, A. T., N. W. Bulkmans, J. Berkhof, A. T. Lorincz, C. J. Meijer, and P. J. Snijders. 2006. Cross-sectional comparison of an automated Hybrid Capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J. Clin. Microbiol. 44:3680-3685.
9. Hesselink, A. T., M. A. van Ham, D. A. Heideman, Z. M. Groothuismink, L. Rozendaal, J. Berkhof, F. J. van Kemenade, L. A. Massuger, W. J. Melchers, C. J. Meijer, and P. J. Snijders. 2008. Comparison of GP5+/6+-PCR and SPF10-line blot assays for detection of high-risk human papillomavirus in samples from women with normal cytology results who develop grade 3 cervical intraepithelial neoplasia. J. Clin. Microbiol. 46:3215-3221.
10. IARC. 2005. Diagnosis and treatment of cervical preinvasive and invasive disease. In IARC handbooks of cancer prevention 2005. IARC Press, Lyon, France.
11. Jones, J., N. G. Powell, A. Tristram, A. N. Fiander, and S. Hibbitts. 2009. Comparison of the PapilloCheck DNA micro-array human papillomavirus detection assay with Hybrid Capture II and PCR-enzyme immunoassay using the GP5/6+ primer set. J. Clin. Virol. 45:100-104.
12. Khan, M. J., P. E. Castle, A. T. Lorincz, S. Wacholder, M. Sherman, D. R. Scott, B. B. Rush, A. G. Glass, and M. Schiffman. 2005. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 97:1072-1079.
13. Mayrand, M. H., E. Duarte-Franco, I. Rodrigues, S. D. Walter, J. Hanley, A. Ferenczy, S. Ratnam, F. Coutlee, and E. L. Franco. 2007. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med. 357:1579-1588.
14. Meijer, C. J., J. Berkhof, P. E. Castle, A. T. Hesselink, E. L. Franco, G. Ronco, M. Arbyn, F. X. Bosch, J. Cuzick, J. Dillner, D. A. Heideman, and P. J. Snijders. 2009. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int. J. Cancer 124:516-520.
15. Munoz, N., F. X. Bosch, S. de Sanjose, R. Herrero, X. Castellsague, K. V. Shah, P. J. Snijders, and C. J. Meijer. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348:518-527.
16. Naucler, P., W. Ryd, S. Tornberg, A. Strand, G. Wadell, K. Elfgren, T. Radberg, B. Strander, O. Forslund, B. G. Hansson, E. Rylander, and J. Dillner. 2007. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N. Engl. J. Med. 357:1589-1597.
17. Ronco, G., P. Giorgi-Rossi, F. Carozzi, M. Confortini, P. P. Dalla, A. Del Mistro, A. Gillio-Tos, D. Minucci, C. Naldoni, R. Rizzolo, P. Schincaglia, R. Volante, M. Zappa, M. Zorzi, J. Cuzick, and N. Segnan. 2008. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J. Natl. Cancer Inst. 100:492-501.
18. Sankaranarayanan, R., B. M. Nene, S. S. Shastri, K. Jayant, R. Muwonge, A. M. Budukh, S. Hingmire, S. G. Malvi, R. Thorat, A. Kothari, R. Chinoy, R. Kelkar, S. Kane, S. Desai, V. R. Keskar, R. Rajeshwarkar, N. Panse, and K. A. Dinshaw. 2009. HPV screening for cervical cancer in rural India. N. Engl. J. Med. 360:1385-1394.
19. Schmitt, M., B. Dondog, T. Waterboer, and M. Pawlita. 2008. Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J. Clin. Microbiol. 46:1050-1059.
20. Snijders, P. J., A. J. van den Brule, and C. J. Meijer. 2003. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J. Pathol. 201:1-6.
21. Söderlund-Strand, A., J. Carlson, and J. Dillner. 2009. Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus. J. Clin. Microbiol. 47:541-546.
22. van den Brule, A. J., R. Pol, N. Fransen-Daalmeijer, L. M. Schouls, C. J. Meijer, and P. J. Snijders. 2002. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J. Clin. Microbiol. 40:779-787.